Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical ...
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. Read more about PFE stock here.
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...